TCR 1672
Alternative Names: TCR-1672Latest Information Update: 01 Feb 2024
At a glance
- Originator Beijing Tide Pharmaceutical
- Class Analgesics; Antitussives; Small molecules
- Mechanism of Action Purinergic P2X3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cough; Pain
Most Recent Events
- 23 Jan 2024 Phase-I clinical trials in Cough (PO) (Sino Biopharmaceutical pipeline, Janaury 2024)
- 23 Jan 2024 Phase-I clinical trials in Pain (PO) (Sino Biopharmaceutical pipeline, Janaury 2024)
- 19 Jan 2024 Beijing Tide Pharmaceutical plans a phase I/II trial for Cough (Treatment-experienced) (PO) in February 2024 (NCT06213363)